Actoplus Met XR is a Oral Tablet, Film Coated, Extended Release in the Human Prescription Drug category. It is labeled and distributed by Takeda Pharmaceuticals America, Inc.. The primary component is Pioglitazone Hydrochloride; Metformin Hydrochloride.
Product ID | 64764-310_12f6dfdd-309c-44a9-86bf-664c449f5ddb |
NDC | 64764-310 |
Product Type | Human Prescription Drug |
Proprietary Name | Actoplus Met XR |
Generic Name | Pioglitazone And Metformin Hydrochloride |
Dosage Form | Tablet, Film Coated, Extended Release |
Route of Administration | ORAL |
Marketing Start Date | 2010-06-11 |
Marketing End Date | 2022-09-30 |
Marketing Category | NDA / NDA |
Application Number | NDA022024 |
Labeler Name | Takeda Pharmaceuticals America, Inc. |
Substance Name | PIOGLITAZONE HYDROCHLORIDE; METFORMIN HYDROCHLORIDE |
Active Ingredient Strength | 30 mg/1; mg/1 |
Pharm Classes | Peroxisome Proliferator-activated Receptor Activity [MoA],PPAR alpha [CS],PPAR gamma [CS],Thiazolidinedione [EPC],Thiazolidinediones [CS],Peroxisome Proliferator Receptor alpha Agonist [EPC],Peroxisome Proliferator Receptor gamma Agonist [EPC],Biguanide [EPC],Biguanides [CS] |
NDC Exclude Flag | N |
Marketing Start Date | 2010-06-11 |
Marketing End Date | 2022-09-30 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA022024 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2010-06-11 |
Marketing End Date | 2022-09-30 |
Marketing Category | NDA |
Application Number | NDA022024 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2010-06-11 |
Marketing End Date | 2022-09-30 |
Marketing Category | NDA |
Application Number | NDA022024 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2010-06-11 |
Marketing End Date | 2022-09-30 |
Marketing Category | NDA |
Application Number | NDA022024 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2010-06-11 |
Marketing End Date | 2022-09-30 |
Marketing Category | NDA |
Application Number | NDA022024 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2010-06-11 |
Marketing End Date | 2022-09-30 |
Ingredient | Strength |
---|---|
PIOGLITAZONE HYDROCHLORIDE | 30 mg/1 |
SPL SET ID: | f986164c-51a7-41c2-8952-511b8f46d593 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI | |
UPC Code |
NDC | Brand Name | Generic Name |
---|---|---|
64764-155 | Actoplus Met | pioglitazone and metformin hydrochloride |
64764-158 | Actoplus Met | pioglitazone and metformin hydrochloride |
64764-310 | Actoplus Met | pioglitazone and metformin hydrochloride |
64764-510 | Actoplus Met | pioglitazone and metformin hydrochloride |
0093-7677 | Pioglitazone and Metformin Hydrochloride | Pioglitazone and Metformin Hydrochloride |
0093-7678 | Pioglitazone and Metformin Hydrochloride | Pioglitazone and Metformin Hydrochloride |
42291-512 | Pioglitazone and Metformin Hydrochloride | Pioglitazone and Metformin Hydrochloride |
42291-513 | Pioglitazone and Metformin Hydrochloride | Pioglitazone and Metformin Hydrochloride |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
ACTOPLUS MET 78218773 3149378 Live/Registered |
TAKEDA PHARMACEUTICAL COMPANY LIMITED 2003-02-25 |
ACTOPLUS MET 78174989 not registered Dead/Abandoned |
Takeda Chemical Industries, Ltd. 2002-10-16 |